By Karen Roman
Imviva Biotech said it will present its progress in allogenic cell therapy candidates in two oral presentations and five poster presentations at the 67th American Society of Hematology (ASH) Annual Meeting, to be held on December 6-9, 2025, in Orlando, Florida.
The presentation will feature the company’s CAR-T cell therapy for multiple hematological conditions including severe aplastic anemia and acute lymphoblastic leukemia, called CTD402 and CTA311, the company stated.
“We will share the breadth and depth of our ANSWER platform, which addresses many limitations encountered by autologous and allogeneic CAR-T cell therapy,” said Jan Davidson-Moncada, MD, PhD., Imviva’s Chief Medical Officer. “This will include the breakthrough progress of our lead investigational product, CTD402, in treating leukemias.”
READ MORE
NYSE Firesides Scheduled Dec 9, 2025 & Feb 3, 2026
Never Miss our Weekly Highlights HERE
